

Day 1 August 18, 2023	Abstract ID	Title	Presenter	Moderator
08.00-09.00	Trainee session (Thai)	Minimizing Toxicity in the Neoadjuvant Treatment for Rectal Cancer	SONGPHOL MALAKORN, M.D. Assistant Professor KEERATIKARN BOONYAWAN, M.D. Associate Professor KRITTIYA KORPHAISARN, M.D.	Assistant Professor SUEBPONG TANASANVIMON, M.D.
09.00-09.10		Opening and welcome message	Assistant Professor CHARUWAN AKEWANLOP, M.D. Assistant Professor SUEBPONG TANASANVIMON, M.D.	President, Thai Society of Clinical Oncology Scientific Chairman, Thai Society of Clinical Oncology
09.15-09.25	LBA2	Colorectal Cancer PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).	Associate Professor KRITTIYA KORPHAISARN, M.D.	Associate Professor EKAPHOP SIRACHAINAN, M.D.
09.25-09.35	LBA3503	Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.	TEERADA SIRIPOON, M.D.	
09.35-09.45	3508	Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.	NATTAYA TEEYAPUN, M.D.	
09.45-10.00		Discussion / Q&A	Assistant Professor SUEBPONG TANASANVIMON, M.D.	
10.00-10.20		Exhibition		
10.20-11.05	Bristol Myers Squibb Tea Symposium 1	Advancing Survivorship Frontline Immunotherapy in ESCC	Professor Chih-Hung Hsu, MD, PhD Department of Medical Oncology, National Taiwan University Cancer Center, TAIPEI, TAIWAN Associate Professor KRITTIYA KORPHAISARN, M.D. Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Siriraj hospital, Mahidol University	Associate Professor CHAIYUT CHAROENTUM, M.D.

Day 1 August 18, 2023	Abstract ID	Title	Presenter	Moderator
		CNS, Melanoma and Sarcoma		
11.10-11.25	LBA1*	INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.	Associate Professor SITH SATHORNTHUMETEE, M.D.	TOUCH ATIVITAVAS, M.D.
11.25-11.35	9508*	Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.	Associate Professor KOSIN WIRASORN, M.D.	
11.35-11.45	ID11503	A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).	Assistant Professor JOMJIT CHANTHARASAMEE, M.D.	
11.45-11.55	LBA11504*	Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.	Assistant Professor JOMJIT CHANTHARASAMEE, M.D.	
11.55-12.10		Discussion / Q&A	Associate Professor CHANIDA VINAYANUWATTIKUN, MD., PH.D.	
12.15-13.00	Pfizer Lunch Symposium 1	Raising the bar for patients with ALK+ NSCLC throughout their treatment journey	Dr. Jessica J. Lin	Associate Professor CHAIYUT CHAROENTUM, M.D.
13.00-13.20		Exhibition		
		GI non-colorectal cancer		
13.20-13.30	4002	Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.	Associate Professor KOSIN WIRASORN, M.D.	Associate Professor CHAIYUT CHAROENTUM, M.D.
13.30-13.40	ID4006	Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.	Assistant Professor THATTAN SUKSOMBOONCHAROEN, M.D.	
13.40-13.50	4000*	ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.	Assistant Professor TEERAPAT UNGTRAKUL, M.D.	
13.50-14.05		Discussion / Q&A	Associate Professor NUTTAPONG NGAMPHAIBOON,	

Day 1 August 18, 2023	Abstract ID	Title	Presenter	Moderator
14.10-14.55	Astellas Tea Symposium 2	Improving survival outcome with first ADC approval in Thailand for la/mUC patient	Prof. Thomas Powles Barts Cancer Centre, St. Bartholomew's Hospital, UK	Assistant Professor CHARUWAN AKEWANLOP, M.D.
14.55-15.15		Exhibition		
		Genitourinary cancer		
15.15-15.25	LBA4500	Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.	Assistant Professor JARIN CHINDAPRASIT, M.D.	Assistant Professor CHARUWAN AKEWANLOP, M.D.
15.25-15.35	LBA5000	Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.	Assistant Professor PONGWUT DANCHIVIJITR, M.D.	
15.35-15.45	ID5004	TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.	NATTAYA POOVORAWAN, M.D.	
15.45-16.00		Discussion / Q&A	PHICHAI CHANSRIWONG, M.D.	
16.05-16.50	Ipsen Evening Symposium	Practice Pearls for Optimizing Advanced RCC Management	Assoc. Prof. Ravindran Kanesvaran National Cancer Centre Singapore, Singapore	PHICHAI CHANSRIWONG, M.D. NATTAYA POOVORAWAN, M.D.
18.00		Faculty dinner		